These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 18695136

  • 1. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.
    J Natl Cancer Inst; 2008 Aug 20; 100(16):1167-78. PubMed ID: 18695136
    [Abstract] [Full Text] [Related]

  • 2. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
    Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I, Ottewell PD, Holen I.
    Cell Oncol (Dordr); 2013 Dec 20; 36(6):505-14. PubMed ID: 24177992
    [Abstract] [Full Text] [Related]

  • 3. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P.
    J Natl Cancer Inst; 2007 Feb 21; 99(4):322-30. PubMed ID: 17312309
    [Abstract] [Full Text] [Related]

  • 4. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
    Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I.
    Int J Cancer; 2010 Jan 15; 126(2):522-32. PubMed ID: 19621384
    [Abstract] [Full Text] [Related]

  • 5. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
    Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I.
    Mol Cancer Ther; 2009 Oct 15; 8(10):2821-32. PubMed ID: 19789217
    [Abstract] [Full Text] [Related]

  • 6. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, Ryu K, Sakabe T, Itoi M, Ashihara E, Maekawa T, Fushiki S, Kubo T.
    Oncol Rep; 2010 Jul 15; 24(1):233-9. PubMed ID: 20514467
    [Abstract] [Full Text] [Related]

  • 7. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW, Ko CH, Yue GG, Gao S, Lee JK, Li G, Fung KP, Leung PC, Evdokiou A, Lau CB.
    J Cancer Res Clin Oncol; 2015 Jun 15; 141(6):1025-36. PubMed ID: 25431338
    [Abstract] [Full Text] [Related]

  • 8. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I.
    Clin Cancer Res; 2008 Jul 15; 14(14):4658-66. PubMed ID: 18628481
    [Abstract] [Full Text] [Related]

  • 9. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA, Folks K, Warram J, Chanda D, Wang D, Zinn KR.
    Cancer Biol Ther; 2009 Jun 15; 8(12):1109-16. PubMed ID: 19652526
    [Abstract] [Full Text] [Related]

  • 10. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
    Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL, Holen I.
    Clin Cancer Res; 2014 Jun 01; 20(11):2922-32. PubMed ID: 24687923
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
    Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE, Holen I.
    Breast Cancer Res Treat; 2012 Jun 01; 133(2):523-36. PubMed ID: 21956211
    [Abstract] [Full Text] [Related]

  • 12. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL, Ottewell PD.
    Clin Exp Metastasis; 2016 Mar 01; 33(3):211-24. PubMed ID: 26585891
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
    Ubellacker JM, Haider MT, DeCristo MJ, Allocca G, Brown NJ, Silver DP, Holen I, McAllister SS.
    Breast Cancer Res; 2017 Mar 06; 19(1):23. PubMed ID: 28264701
    [Abstract] [Full Text] [Related]

  • 15. Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin.
    Hattori Y, Shibuya K, Kojima K, Miatmoko A, Kawano K, Ozaki K, Yonemochi E.
    Int J Oncol; 2015 Jul 06; 47(1):211-9. PubMed ID: 25955490
    [Abstract] [Full Text] [Related]

  • 16. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
    Hashimoto K, Masumori N, Tanaka T, Maeda T, Kobayashi K, Kitamura H, Hirata K, Tsukamoto T.
    Prostate; 2013 Apr 06; 73(5):500-11. PubMed ID: 22996996
    [Abstract] [Full Text] [Related]

  • 17. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
    Clyburn RD, Reid P, Evans CA, Lefley DV, Holen I.
    Cancer Chemother Pharmacol; 2010 Apr 06; 65(5):969-78. PubMed ID: 19730863
    [Abstract] [Full Text] [Related]

  • 18. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
    Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A.
    Clin Cancer Res; 2009 May 15; 15(10):3451-61. PubMed ID: 19401351
    [Abstract] [Full Text] [Related]

  • 19. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
    Jia X, Cheng J, Shen Z, Shao Z, Liu G.
    Mol Med Rep; 2018 Apr 15; 17(4):5470-5476. PubMed ID: 29393454
    [Abstract] [Full Text] [Related]

  • 20. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.
    Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Pinzòn-Daza ML, Giordano A, Desiderio V, Ghigo D, De Rosa G, Caraglia M, Riganti C.
    Oncotarget; 2016 Apr 12; 7(15):20753-72. PubMed ID: 26980746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.